Arcus Biosciences President Juan Jaen Sells Over $2 Million in Shares

Arcus Biosciences, Inc. (NYSE: RCUS) experienced a significant transaction on December 4, 2023, when its President, Juan Jaen, sold 82,997 shares of the company’s stock. The shares were sold at an average price of $24.71, amounting to a total value of $2,050,855.87. Following this sale, Jaen holds 954,063 shares, valued at approximately $23,574,896.73, reflecting an 8.00% decrease in his ownership stake.

This transaction was disclosed in a filing with the Securities and Exchange Commission, providing transparency regarding insider trading activities.

Stock Performance and Market Analysis

As of December 5, 2023, shares of Arcus Biosciences opened at $25.50. The company’s stock has shown positive momentum, with a 1.0% increase. The fifty-day moving average stands at $19.25, while the 200-day moving average is at $13.13. Arcus has a market capitalization of $2.75 billion and a current ratio and quick ratio, both at 3.65. The company also has a debt-to-equity ratio of 0.22.

Over the past year, the stock has fluctuated significantly, with a 52-week low of $6.50 and a 52-week high of $26.40. The price-to-earnings (P/E) ratio is currently -7.41, indicating losses relative to earnings.

Recent Financial Results

On October 28, 2023, Arcus Biosciences announced its quarterly earnings, reporting an earnings per share (EPS) of ($1.27). This figure surpassed the consensus estimate of ($1.33) by $0.06. The company generated $26.00 million in revenue for the quarter, exceeding the expected $19.89 million. Despite this positive news, Arcus reported a negative net margin of 136.40% and a negative return on equity of 68.17%, with quarterly revenue down 45.8% compared to the previous year.

Equities research analysts forecast that Arcus Biosciences will report an EPS of ($3.15) for the current fiscal year.

Analyst Ratings and Future Outlook

Recent analyst ratings reflect a mixed outlook for Arcus Biosciences. Weiss Ratings reaffirmed a “sell (d-)” rating on October 8, 2023. Conversely, Bank of America raised its price target from $17.00 to $26.00 with a “neutral” rating on November 28, 2023. HC Wainwright increased its price target from $24.00 to $28.00 and maintained a “buy” rating. Citigroup also raised its price objective from $54.00 to $56.00, maintaining a “buy” rating, while The Goldman Sachs Group adjusted its target from $14.00 to $16.00, continuing a “neutral” stance.

Overall, seven analysts currently rate the stock as a “Buy,” two have assigned a “Hold” rating, and one has given it a “Sell” rating. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a target price of $29.44.

Arcus Biosciences, a clinical-stage biopharmaceutical company, specializes in the development and commercialization of cancer therapies in the United States. Its pipeline includes Domvanalimab, an anti-TIGIT antibody in Phase 2 and Phase 3 trials, and AB308, an investigational anti-TIGIT monoclonal antibody currently in a Phase 1b trial focused on advanced solid and hematologic malignancies.

For ongoing updates, interested parties can subscribe to daily summaries of news and analyst ratings for Arcus Biosciences.